Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 August 2021 | Story Dr Cindé Greyling | Photo Sonia Small
Lacea Loader, an award-winning communications professional.

Lacea Loader is an award-winning communications professional who heads the UFS Department of Communication and Marketing as Director. She works with a multi-talented team that takes care of all aspects of corporate communication and marketing at the UFS. 

What is the best thing about your job?
Having a portfolio that is ever-changing and that provides me with a broad perspective of the university’s business, which is enriching and insightful. Most of all, I enjoy the people I work with in every area of my job. In general, I stand amazed at the commitment and dedication of our staff, especially during the national lockdown. It has been encouraging to experience how my team has grown and developed their skills and transitioned to the virtual workspace during this time.  

What is the best and worst decisions you have ever made?
I learn from every decision, whether it has a good or challenging impact on my life. Marrying my best friend from school and raising two beautiful, strong, and independent children are the best decisions I could have made.

What was/is the biggest challenge of your career?
The balancing act. Balancing work life and personal life; this remains a challenge throughout my career. I am trying, but I still don’t get it right!

What does the word woman mean to you?
Being able to be powerful and assertive, yet kind, gentle, compassionate, vulnerable, and understanding at the same time. 

Which woman inspires you, and why?
I work with a team of exceptional women leaders who inspire me every day. Many women at our university have reached incredible heights and put the institution on the national and international stage with their achievements. I salute all my women colleagues in whatever role they play. Also, my involvement with professional organisations and international awards programmes has given me the opportunity to work with so many women across the world in the field of communication and marketing who are making a difference in our profession. 

What advice would you give to the 15-year-old you?
Grab the opportunities that may come your way, and always think of ways to enrich yourself personally and as a professional. Remember that your character is like a tree and your reputation is like its shadow. The shadow is what others think of you; the tree is the real you.

What is the one self-care thing that you do? 
I make time to drink tea, and lots of it! Walking with my husband, spending time with my family and friends, camping and enjoying nature are some of my favourite things.

What makes you a woman of quality, impact, and care?
My intuition and sixth sense, positive mindset, and deep belief that nothing will get me down. If you ask my children, they will say it is my work ethic – as it inspires them in their studies, my kind heart, and my resilience. 
 
I cannot live without … my music playlist and a good night’s sleep.
My secret weapon is … knowing when to pause and to take time out.
I always have … a plan B.
I will never … jump from anything higher than five times my length.
I hope … to visit Easter Island, Alaska, and Norway.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept